Publications by authors named "A N Chesnokov"
Article Synopsis
- - Since 2013, there have been 167 cases of people infected with special flu viruses from pigs in the U.S. called swine-origin influenza A.
- - Most of these viruses had a change in their genes that makes them resistant to certain medicines, but none were resistant to another type of medicine called neuraminidase inhibitors.
- - Scientists did tests to find out how well these viruses respond to treatments and discovered that one specific change in the virus made it much harder to treat with a medicine called baloxavir.
Influenza C virus susceptibility to antivirals with different mechanisms of action.
Antimicrob Agents Chemother
May 2024
Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC 8-22 nM) against type C viruses from six lineages.
View Article and Find Full Text PDFInfluenza virus neuraminidase (NA) can act as a receptor-binding protein, a role commonly attributed to hemagglutinin (HA). In influenza A(H3N2) viruses, three NA amino acid residues have previously been associated with NA-mediated hemagglutination: T148, D151, and more recently, H150. These residues are part of the 150-loop of the NA monomer.
View Article and Find Full Text PDFArticle Synopsis
- Clade 2.3.4.4b HPAI A(H5N1) viruses have shown potential drug resistance, with about 0.8% of analyzed strains exhibiting markers for resistance to FDA-approved antivirals, indicating a possible public health threat.
- Testing revealed that most of these viruses remain susceptible to existing antivirals, particularly favoring investigational options like AV5080 over conventional treatments.
- Continued surveillance of these viruses is crucial for understanding their evolution and refining strategies for antiviral stockpiling to mitigate potential health risks.
Year-round virological characterization of circulating epidemic influenza viruses is conducted worldwide to detect the emergence of viruses that may escape pre-existing immunity or acquire resistance to antivirals. High throughput phenotypic assays are needed to complement the sequence-based analysis of circulating viruses and improve pandemic preparedness. The recent entry of a polymerase inhibitor, baloxavir, into the global market further highlighted this need.
View Article and Find Full Text PDF